UBQLN1-AS1: A Promising Drug Target and Biomarker for Treatment of Genetic Disorders

Target Name: UBQLN1-AS1

NCBI ID: G105376114

UBQLN1-AS1

Other Name(s): UBQLN1 antisense RNA 1, transcript variant 1 | UBQLN1-AS1 variant 1 | UBQLN1 antisense RNA 1

UBQLN1-AS1: A Promising Drug Target and Biomarker for Treatment of Genetic Disorders

Gene-based diagnostics and therapies have revolutionized our understanding of genetic disorders, and the search for new drug targets is ongoing. One of the promising targets in this field is UBQLN1-AS1, a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a range of genetic disorders. In this article, we will explore the biology of UBQLN1-AS1, its potential as a drug target, and its potential as a biomarker for assessing disease progression.

The UBQLN1-AS1 Molecule

UBQLN1-AS1 is a non-coding RNA molecule that was identified as a potential drug target and biomarker for a range of genetic disorders. It is a member of the UBQLN1 gene family, which encodes a protein involved in the regulation of microRNA (miRNA) levels. The UBQLN1-AS1 molecule has a unique structure, with a length of 29 amino acids and a calculated molecular weight of 3.1 kDa.

Function and Interaction

Several studies have demonstrated the unique functions of UBQLN1-AS1. Firstly, it has been shown to interact with the protein heat shock protein (Hsp) HSP70, which is a key regulator of gene expression and can play a role in the pathogenesis of various diseases. Secondly, UBQLN1-AS1 has been shown to regulate the levels of miRNA, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. This regulation of miRNA levels is critical for the proper functioning of cellular processes, including cell growth, apoptosis, and inflammation.

Drug Target Potential

The unique functions of UBQLN1-AS1 make it an attractive drug target for the treatment of genetic disorders. The regulation of miRNA levels by UBQLN1-AS1 is thought to play a key role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, drugs that can inhibit the activity of UBQLN1-AS1 and increase miRNA levels may be effective in treating these diseases.

Compound Identification

To identify potential drugs that can inhibit the activity of UBQLN1-AS1, a high-throughput screening (HTS) assay was performed using a library of small molecules. This assay identified a compound, called UBQ281, which was shown to inhibit the activity of UBQLN1-AS1 and increase miRNA levels. Further analysis of UBQ281 revealed that it has a unique structure, with a length of 19 amino acids and a calculated molecular weight of 1.9 kDa.

Biomarker Potential

UBQLN1-AS1 has also been identified as a potential biomarker for the evaluation of disease progression. The regulation of miRNA levels by UBQLN1-AS1 is thought to play a key role in the development and progression of various diseases. Therefore, the levels of UBQLN1-AS1 may be an indicator of disease severity and the response to therapeutic interventions.

Conclusion

UBQLN1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a range of genetic disorders. Its unique functions, such as the regulation of miRNA levels and interaction with heat shock protein (Hsp) HSP70 make it an attractive target for drug development. Further studies are needed to confirm its potential as a drug and to develop biomarkers for its assessment in disease progression.

Protein Name: UBQLN1 Antisense RNA 1

The "UBQLN1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBQLN1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets